GlassScriptPhysician profile
Wasim A Haque
NPI 1679762405
$27,048.67
in general payments reported to CMS, 2019-2025
73 companies · $3,030 in 2025
The $3,030 reported for 2025 was more than what 83% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $5,947 · 2020: $2,556 · 2021: $2,764 · 2022: $7,565 · 2023: $1,734 · 2024: $3,452 · 2025: $3,030.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,294 · Travel and Lodging: $807 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,294.33 |
| Travel and Lodging | $807.32 |
| Education | $114.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acerus Pharmaceuticals Corporation | $5,643.18 | 2021-2022 | |
| Corcept Therapeutics | $3,672.34 | 2019-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $1,365.64 | 2019-2023 | Farxiga |
| Mannkind Corporation | $1,284.13 | 2019-2025 | Afrezza |
| Eli Lilly and Company | $1,277.44 | 2022-2024 | |
| Novo Nordisk INC | $1,132.86 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,122.07 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $708.52 | 2019-2025 | |
| Amgen INC. | $701.28 | 2019-2025 | Tepezza, Evenity, Prolia |
| Insulet Corporation | $616.66 | 2019-2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $589.39 | 2019-2025 | Jardiance |
| Antares Pharma, INC. | $585.73 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Abbott Laboratories | $537.15 | 2019-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $442.70 | 2019-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $421.34 | 2020-2025 | Gvoke Hypopen, Recorlev |
Show all 71 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $381.65 | 2021-2025 | |
| Amarin Pharma, INC. | $359.66 | 2019-2023 | |
| Medtronic, INC. | $352.58 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Medtronic Minimed, INC. | $341.49 | 2019-2020 | |
| Abbvie INC. | $326.88 | 2019-2024 | |
| Ibsa Pharma INC. | $285.02 | 2019-2025 | Tirosint, Tirosint, Licart |
| Echosens North America, INC. | $278.51 | 2023 | Fibroscan |
| Tandem Diabetes Care, INC. | $275.19 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Esperion Therapeutics, INC. | $269.91 | 2020-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $252.27 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $231.13 | 2019-2023 | Unithroid |
| Radius Health, INC. | $222.71 | 2019-2025 | Tymlos |
| Clarus Therapeutics INC. | $220.92 | 2021 | |
| Vivus LLC | $188.64 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $186.91 | 2024-2025 | |
| Madrigal Pharmaceuticals | $170.68 | 2025 | Rezdiffra |
| Zealand Pharma US, INC. | $163.96 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $138.60 | 2019-2023 | Cycloset |
| Cequr Corporation | $127.25 | 2022-2025 | Cequr Simplicity |
| Verity Pharmaceuticals INC. | $126.33 | 2024-2025 | Tlando |
| Ascensia Diabetes Care US INC. | $123.63 | 2021-2025 | |
| Recordati_rare_diseases_inc. | $101.93 | 2021-2023 | Isturisa, Signifor Lar |
| Nevro Corp. | $99.07 | 2021-2022 | |
| Sequel Med Tech, LLC | $96.97 | 2025 | Twiist |
| Companion Medical, INC. | $96.70 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $94.52 | 2023-2025 | Strensiq |
| Acella Pharmaceuticals, LLC | $94.38 | 2021-2025 | NP Thyroid 60 |
| Aytu Biopharma, INC. | $85.16 | 2019-2020 | |
| Valeritas, INC. | $81.29 | 2019 | |
| Currax Pharmaceuticals LLC | $79.09 | 2019-2025 | Contrave |
| Beta Bionics, INC. | $76.70 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Shire North American Group INC | $75.11 | 2019 | |
| Eusa Pharma (US) LLC | $73.05 | 2022 | |
| Boston Scientific Corporation | $72.49 | 2025 | Wavewriter Alpha Prime 16 |
| Ascendis Pharma Endocrinology INC | $69.75 | 2023-2025 | Yorvipath |
| Pfizer INC. | $64.76 | 2019-2023 | |
| Horizon Therapeutics Plc | $63.90 | 2021-2023 | Tepezza |
| Astellas Pharma US INC | $56.90 | 2024-2025 | Veozah |
| Ultragenyx Pharmaceutical INC. | $56.26 | 2020-2022 | |
| Amphastar Pharmaceuticals, INC. | $55.21 | 2025 | |
| Rhythm Pharmaceuticals, INC. | $50.83 | 2024-2025 | Imcivree |
| Arbor Pharmaceuticals, INC. | $45.42 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.03 | 2021 | |
| Alvogen INC | $34.96 | 2022-2025 | Teriparatide |
| Novartis Pharmaceuticals Corporation | $34.00 | 2022-2023 | |
| Avvisto Therapeutics, LLC | $33.19 | 2024-2025 | Cycloset |
| Becton, Dickinson and Company | $28.35 | 2019-2020 | |
| Sandoz INC. | $27.49 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $23.14 | 2023 | Livalo |
| Tolmar, INC. | $20.09 | 2023 | |
| Azurity Pharmaceuticals, INC. | $17.70 | 2025 | Azmiro |
| Amryt Pharma Holdings LTD | $17.68 | 2023 | Mycapssa |
| Regeneron Healthcare Solutions, INC. | $16.84 | 2025 | Evkeeza |
| Evoke Pharma, INC. | $16.12 | 2024 | |
| Opko Pharmaceuticals, LLC | $14.76 | 2019 | |
| Lifescan, INC. | $13.48 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$42,488.17 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wasim Haque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.